Gregory Mattingly

Jan 29, 2024 | hcplive.com | Andrew Cutler |Gregory Mattingly

SummaryIn addition to the dextromethorphan-bupropion combination, the clinicians review other evidence-based treatments for anhedonia. These include medications modulating dopamine, glutamate, kappa opioid receptors, and psychedelics. Lifestyle approaches like exercise, diet, sleep, social connection, and purpose are also critical, improving motivation and pleasure by enhancing BDNF, endorphins, and dopamine while decreasing inflammation.

Dec 27, 2023 | psychiatrist.com | Andrew Cutler |Gregory Mattingly |Susan G. Kornstein |Scott Aaronson

ABSTRACTObjective: Zuranolone is a positive allosteric modulator of both synaptic and extrasynaptic γ-aminobutyric acid (GABA) type A receptors and a neuroactive steroid approved in the United States as an oral, once-daily, 14-day treatment course for adults with postpartum depression and under investigation for adults with major depressive disorder (MDD).

Dec 14, 2023 | hcplive.com | Andrew Cutler |Gregory Mattingly

SummaryThe clinicians identify major challenges in diagnosing and managing depression, including inadequately addressing symptoms like anhedonia, cognition, and motivation that drive disability. Current antidepressants like SSRIs often don't improve these hard-to-treat symptoms. SSRIs also worsen cognition by decreasing dopamine. Another limitation of SSRIs is their delayed therapeutic benefit, taking 4-6 weeks to relieve symptoms despite increasing serotonin right away.